Participated · Equity · Jan 2025

Robeauté is developing a therapeutic microrobotic platform built around a universal robotic carrier with interchangeable micro-extensions that can deliver drugs, implant electrodes, collect tissue samples or capture real-time data from deep in the brain. The active robots, continuously tracked by ultrasound, move along curved, non-linear paths inside brain tissue, providing surgeons with unprecedented control compared with magnetically driven probes. The company holds more than 50 patents and positions its platform to address large markets such as brain cancer, biopsies, targeted drug delivery and brain–computer interfaces. Founded in 2017 by robotics veteran Bertrand Duplat and operations specialist Joana Cartocci, Robeauté operates from Paris and recently opened a U.S. subsidiary to facilitate clinical trials and commercialization. Its first-in-human studies are targeted for completion by the end of 2026, with the U.S. expected to be the initial launch market due to a more collaborative regulatory environment. In January 2025 the company secured $28 million in new funding, enabling it to double its team and accelerate product development. While revenue and user numbers have not been disclosed, the fresh capital provides runway for expanded hiring across scientific, engineering, quality, regulatory and go-to-market roles.

Led · Series C · Jan 2016

Jan Medical is a privately held, emerging medical technology company based in Mountain View, Calif. It developed BrainPulse, a novel, non-invasive, portable brain sensing system that captures a physiological signal utilizing cardiac output to measure vasculature and brain tissue conditions. The device is intended as a rapid aid to help diagnose abnormal neurological conditions including concussion and stroke. Clinical work reported in the articles includes a Stanford trial that detected and longitudinally observed sports-related concussion and a UCSF study that detected vasospasm; additional clinical trials in concussion detection and vasospasm are ongoing. Jan Medical plans to use new funding to complete ongoing clinical trials and to pursue a de novo filing with the FDA and CE Mark registration in the EU. The BrainPulse system is an investigational device that has not received FDA clearance and is not commercially available. Jan Medical develops the Nautilus NeuroWave, a portable, non‑invasive brain‑sensing system intended as a rapid aid to diagnose cerebral abnormalities when conventional imaging is ineffective or unavailable. The company says Nautilus is designed to provide simple, reliable monitoring for patients recovering from subarachnoid hemorrhage (SAH) and to detect and track recovery from sports‑related concussion. Jan Medical completed a vasospasm study at UCSF Hospital and has an investigator‑led trial at Stanford investigating concussion applications. The company announced Series B funding efforts and a corporate collaboration with Brainlab to complete two clinical trials and to file two product 510(k)s with the FDA. Jan Medical is privately held and describes the Nautilus system as investigational and limited by U.S. federal law to investigational use. Management states the Series B validates the platform’s potential amid a challenging funding environment. Jan Medical is a privately held medical technology company based in Mountain View, Calif., that has developed a portable brain‑sensing system intended to rapidly diagnose and aid assessment of strokes. The company describes its device as the world’s first and only portable brain sensing system designed to detect stroke within minutes and help distinguish ischemic from hemorrhagic events. Clinical data on the system were disclosed at the annual meeting of the Society of Interventional Radiology, with Dr. Eric Aldrich serving as principal investigator. Jan plans to use new capital to commence and complete two clinical trials and to prepare and file two product 510(k) submissions with the FDA. CEO Paul Lovoi stated the technology could improve triage, speed treatment, lower costs, and reduce patient risk. The Jan Medical system is an investigational device limited by U.S. federal law to investigational use.